Settlement of India/EU WTO Dispute re Seizures of In-Transit Medicines: Why the Proposed EU Border Regulation Isn\u27t Good Enough by Baker, Brook K.
American University Washington College of Law 
Digital Commons @ American University Washington College of 
Law 
Joint PIJIP/TLS Research Paper Series 
1-2012 
Settlement of India/EU WTO Dispute re Seizures of In-Transit 
Medicines: Why the Proposed EU Border Regulation Isn't Good 
Enough 
Brook K. Baker 
Northeastern University School of Law, b.baker@neu.edu 
Follow this and additional works at: https://digitalcommons.wcl.american.edu/research 
 Part of the Intellectual Property Law Commons, and the International Trade Law Commons 
Recommended Citation 
Baker, Brook K. 2012. Settlement of India/EU WTO Dispute re Seizures of In-Transit Medicines: Why the 
Proposed EU Border Regulation Isn't Good Enough. PIJIP Research Paper no. 2012-02 American 
University Washington College of Law, Washington, D.C. 
This Article is brought to you for free and open access by the Program on Information Justice and Intellectual 
Property and Technology, Law, & Security Program at Digital Commons @ American University Washington College 
of Law. It has been accepted for inclusion in Joint PIJIP/TLS Research Paper Series by an authorized administrator 




SETTLEMENT OF INDIA/EU WTO DISPUTE RE 
SEIZURES OF IN-TRANSIT MEDICINES:  
WHY THE PROPOSED EU BORDER 
REGULATION ISN‟T GOOD ENOUGH 
 
Professor Brook K. Baker




European Customs officials have used fictive patent rights to justify the 
seizure of lawful generic medicines produced in India and destined for non-
European markets.  Following a public outcry and initiation of two WTO 
complaints, the EU has proposed amendments to Border Regulations 
Measure 1383/2003.  The Proposed Border Regulation in its current form 
will not adequately resolve the risk of interception in Europe of medicines 
lawfully manufactured and exported from India and destined for lawful 
import and consumption in a non-EU country.  This analysis concludes that 
multiple weaknesses remain in the Border Regulations, including: (1) 
continued coverage of alleged patent and supplemental protection certificate 
infringement claims that can be based on fictional patent status under 
national law; the addition of utility models; and continued coverage of 
design rights and civil trademark infringement matters that are more 
appropriately addressed in ordinary court proceedings; (2) inappropriate 
application of the law of the in-transit country instead of the law of the 
importing country when assessing an IP infringement claim; (3) unclear 
directives to “consider” the risk of diversion to EU markets with no explicit 
prohibition against seizing in-transit medicines in the absence of such a 
showing and without requirement of clear and convincing evidence of an 
imminent diversion by an identified party; (4) insufficient opportunities to 
be heard for declarants and holders of goods; and (5) insufficient remedies 
for declarants and holders of goods and for purchasers and consumers who 
are proximately harmed by unsuccessful border applications.  
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On July 28, 2011, the Ministry of Commerce and Industry of the 
Government of India announced an “Understanding” in principle with the 
European Union (EU) concerning a pending World Trade Organization 
(WTO) complaint challenging EU customs measures that had been used to 
justify seizures of Indian generic medicines in transit through Europe to 
destinations in Latin America, Oceania, and Africa.
2
 These seizures and the 
EU‟s delayed and defensive response
3
 to early and repeated expressions of 
diplomatic and human rights concerns
4
 prompted India and Brazil to initiate 
dispute resolution procedures – namely preliminary requests for 
                                                 
2
 Press Release, Government of India Ministry of Commerce and Industry, Indian EU 
Reach an Understanding on Issue of Seizure of Indian Generic Drugs in Transit (July 28, 
2011), available at http://pib.nic.in/newsite/erelease.aspx?relid=73554. 
3
 See WTO General Council, Minutes of Meeting, WT/ GC/M/118 (Feb. 3, 2009), 
available at 
http://docsonline.wto.org/GEN_highLightParent.asp?qu=&doc=D%3A%2FDDFDOCUM
ENTS%2FT%2FWT%2FGC%2FM118.DOC.HTM . (arguing that BMR was fully TRIPS-
compliant and that Europe was acting benevolently to prevent trade in “counterfeit” 
medicines that were a risk to public health in developing countries). 
4
 See, e.g., Intervention by India, Agenda Item ‘M’ – Other Business – Public Health 
dimension of the TRIPS Agreement (Feb. 4, 2009), available at http://www.ip-
watch.org/weblog/wp-content/uploads/2009/03/intervention-by-india.doc; Statement by 
Brazil, TRIPS Council Agenda Item M (Other Business), Public Health Dimension of the 
TRIPS Agreement, (Feb. 4, 2009), available at 
http://keionline.org/blogs/2009/03/04/brazilian-intervention-at-trips-council; Letter from 
various NGOs to the Director Generals of the WHO and the WTO Feb. 18, 2009, available 
at http://keionline.org/misc-docs/seizures/WHO_seizures_18feb.pdf; UNITAID Statement 
on Dutch Confiscation of Medicines Shipment, available at 
http://www.unitaid.eu/en/resources/news/156-unitaid-statement-on-dutch-confiscation-of-
medicines-shipment.html; World Health Organization [WHO], Statement – Access to 
Medicines (March 13, 2009), available at 
http://www.who.int/mediacentre/news/statements/2009/access-medicines-
20090313/en/index.html.  
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consultations – against the EU at the World Trade Organization.
5
   
Pursuant to the announced Understanding, the European Union will no 
longer intercept in-transit generic medicines unless there is adequate 
evidence to satisfy customs authorities that there is a substantial likelihood 
of diversion of such medicines to the EU market.  In addition, the EU is to 
issue interim guidelines advising member countries how border 
enforcement should be done.  Finally, the EU has proposed a new 
Regulation (Proposed Border Regulation)
6
 to replace challenged Council 
Regulation (EC) No. 1383/2003, the so-called Border Measures Regulation 
(BMR 1383/2003).
7
  Although India does not completely endorse the 
phrasing of the draft proposal, India will convey its views on the proposal to 
EU during the expected 12-18 month approval process.
8
  There are reports 




In exchange for these undertakings and as long as they are adhered to, 
                                                 
5
 Request for Consultations by India, European Union – Seizure of Generic Drugs in 
Transit, WT/DS408 (May 11, 2011), available at 
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds408_e.htm; Request for 
Consultations by Brazil, European Union – Seizure of Generic Drugs in Transit, 
WT/DS409, available at 
http://www.wto.org/english/tratop_e/dispu_e/cases_e/ds409_e.htm.  The consultations 
were protracted and included premature claims of settlement.  See generally Consultations 
on WTO Drug Transit Case Continue, Intellectual Property Watch, Sept. 16, 2010, 
available at http://www.ip-watch.org/weblog/2010/09/16/consultations-on-wto-case-on-
drugs-in-transit-continue/; C.H. Unnikrishan, India may move WTO as it seeks to resolve 
EU dispute, livemint.com&WSJ (Oct. 10, 2010), 
http://www.livemint.com/2010/10/11225420/India-may-move-WTO-as-it-seeks.html; 
Kaitlin Marla, Minister, India Anticipates European Fix to Law Delaying Generic 




 Proposal for a Regulation of the European Parliament and of the Council 
Concerning Customs Enforcement of Intellectual Property Rights, COM(2011) 285 final 




 Council Regulation 1383/2003, 2003 O.J. (L 196/7), available at http://eur-
lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2003:196:0007:0014:EN:PDF.   
8
 Asit Ranjan Mishra, Generic drugs seizure row:  India, EU Reach ‘Interim 




 Matthias Williams, Update 2-India, EU Health Drugs Seizures Dispute with Interim 
Agreement, REUTERS (July 28, 2011), http://www.reuters.com/article/2011/07/28/india-eu-
drugs-idUSL3E7IS4WW20110728.  
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India has assured the EU that it will not request the establishment of a 
dispute settlement panel at the WTO. However, India retains the option to 
revive the dispute if the EU does not abide by the core principles agreed to 
in the Understanding.
10
 This Understanding between the EU and India does 
not directly impact the parallel WTO dispute filed by Brazil, but as a 
practical matter, Brazil‟s dispute is likely to be suspended pending final 
enactment of the new Regulation.   
The question arises whether India is correct that the Proposed Border 
Regulation in its current form will not adequately resolve the risk of 
interception in Europe of medicines lawfully manufactured and exported 
from India and destined for lawful import and consumption in a non-EU 
country.  This analysis concludes that multiple weaknesses remain, 
including:   
 
1. continued coverage of alleged patent and supplemental protection 
certificate infringement claims that can be based on fictional patent 
status under national law; the addition of utility models; and 
continued coverage of design rights and civil trademark 
infringement matters that are more appropriately addressed in 
ordinary court proceedings; 
2. inappropriate application of the law of the in-transit country instead 
of the law of the importing country when assessing an IP 
infringement claim;  
3. directives to “consider” the risk of diversion to EU markets with no 
explicit prohibition against seizing in-transit medicines in the 
absence of such a showing and without requirement of clear and 
convincing evidence of an imminent diversion by an identified 
party;  
4. insufficient opportunities to be heard for declarants and holders of 
goods; and  
5. insufficient remedies for declarants and holders of goods and for 
purchasers and consumers who are proximately harmed by 
unsuccessful border applications.  
 
Unless these public health weaknesses are addressed, India‟s WTO 
complaint should not be withdrawn.  Moreover, the Proposed Border 
                                                 
10
 EU Agrees to Stop Confiscation of India Generic Drugs, THE ECONOMIC TIMES 
(July 29, 2011), http://articles.economictimes.indiatimes.com/2011-07-
29/news/29829346_1_customs-regulations-indian-generic-drugs-international-intellectual-
property-agreement.  
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Regulation should be rejected by the European Council in its present form. 
 
II. BRIEF BACKGROUND TO THE PROPOSED REGULATION 
 
Between 2008 and 2009 Dutch, and on one occasion German, customs 
officials detained nearly 20 shipments of generic medicines
11
 under the 
authority of BMR 1383/2003.  When interpreting BMR 1383/2003, Dutch 
customs authorities applied the judicially created rule that the IP status of 
in-transit medicines should be judged under the fiction that the medicines 
had been manufactured in the Netherlands.
12
   This interpretation was based 
at least in part on recital no. 8 of BMR 1383/2003 which reads 
“Proceedings initiated to determine whether an intellectual property right 
has been infringed under national law will be conducted with reference to 
the criteria used to establish whether goods produced in that Member State 
infringe intellectual property rights.”  (Emphasis added.)  In some 
circumstances, customs officials acted ex officio to initiate temporary 
seizures based on suspicion of domestic patent law violation under the 
manufacturing fiction. However, they continued such seizures based on 
applications by Big Pharma, which requested impounding and delaying 
shipments of life-saving medicines bound from India, where they had been 
lawfully manufactured and exported, to countries in Africa, Oceania, and 
Latin America, where they would have been lawfully imported, marketed 
and consumed. 
13
  Most of the medicines were seized on the basis of 
                                                 
11
 John Miller & Geeta Anand, India Prepares EU Trade Complaint, WALL ST. J. 
(August 6, 2009), available at 
http://online.wsj.com/article/SB124949598103308449.html?mod=3Dgooglenews_wsj.   
12
 Rechtbanks-Gravenhage [District Court in The Hague], 18 juli 2008, IER 2008, 83 
m.nt. J.G. Kuhlmann (Sosecal v. Sisvel) (Neth.), ), available at 
http://www.eplawpatentblog.com/PDF_December09/The%20Hague%20DC%20Sisvel%20
v%20Sosecal%20EN.pdf ; see Frederick J. Abbott, Seizures of Generic Pharmaceuticals in 
Transit Based on Allegations of Patent Infringement:  A Threat to International Trade, 
Development and Public Welfare, 1 W.I.P.O.J. 43, 47 (2009), available at 
http://www.wipo.int/about-wipo/en/wipo_journal/pdf/wipo_journal_1_1.pdf; Frank 
Eijsvogels, SISVEL V. SOSECAL:  ACTING AGAINST TRANSIT GOODS STILL POSSIBLE UNDER 
THE ANTI PIRACY REGULATION IN THE NETHERLANDS, IP Intelligence Eur. 10 (Howrey 
L.L.P., Amsterdam, Netherlands), 2008. 
13
 E.g., Letter from Merck and Du Pont lawyers to Dr. Reddy‟s Laboratory, Inc. 
(December 24, 2008 ), available at 
http://online.wsj.com/public/resources/documents/eudrugs2009letter1.pdf (stating “the 
Court in the Netherlands has determined that products in transit qualify as products 
infringing intellectual property rights where this would have been the case if the goods 
would have been manufactured in the Netherlands); Letter sent by Eli Lilly lawyers to 
Cipla (December 09, 2008), available at 
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fictional patent violations, but in at least one other instance, generic 
medicines were seized by over-zealous German customs officials on the 
premise that the generic medicine, “amoxicillin,” which as required bore the 
international non-proprietary name, had a “brand” confusingly similar to 
GlaxoSmithKline‟s trademark protected medicine “Amoxil.”
14
  After these 
multiple seizures, customs authorities required that the suspect medicines be 
destroyed, returned to India, or on occasion onward shipped on a delayed 
basis to their ultimate destination.
15
   
Leading European scholars opined that it was unlawful under European 
Council law to apply BMR 1383/2003 to truly in-transit medicines – 
medicines not destined for or likely to be diverted to European Markets.
16
 
The application of fictional IP patent and trademark rights to medicines-in-
transit was also roundly criticized by these same scholars
17
 and by India
18
 
for violating core principles of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS or TRIPS Agreement),
19
 including 
Articles 2, 28, 31, 41, 42, and 52, Articles V and X of the General 
                                                                                                                            
http://online.wsj.com/public/resources/documents/eudrugs2009letter3.pdf (concerning 
Olanzapine en route from India to Peru).   
14
 European Generic Drug Seizures Take Centre Stage at TRIPS Council Meeting, 13 
BRIDGES WEEKLY TRADE NEWS DIGEST (June 10, 2009), available at 
http://ictsd.org/i/news/bridgesweekly/48330/.  
15
 Press Release, supra note 2. 
16
 See, e.g., Henning Grosse Ruse-Khan & Thomas Jaeger, Policing Patents 
Worldwide?  EC Border Measures against Transiting Generic Drugs under EC- and WTO 
Intellectual Property Regimes, 40 INT'L REV. INTELL. PROP. & COMPETITION L. 502 (2009); 
contra Xavier Seuba, Free Trade of Pharmaceutical Products:  The Limits of Intellectual 
Property Enforcement at the Border, INT‟L CENTRE FOR TRADE & SUSTAINABLE DEV. 
(2010), available at http://ictsd.org/downloads/2011/12/free-trade-of-pharmaceutical-
products.pdf. 
17
 Ruse-Khan & Jaeger, supra note 16; Seuba, supra note 16.  Ruse-Khan and Jaeger 
have been the most vociferous in arguing that Article 10 of BMR authorizing seizure goods 
in transit based on alleged IP infringement under of the domestic law of the transit country 
may run counter to Article 52 of TRIPS which requires that border measures be applied 
based on the “law of the country of importation.”   
18
 India WTO Complaint, supra note 3. India‟s comprehensive WTO complaint cited 
violations of Paragraphs 2, 3, 4, and 7 of Article V and Article X of the GATT 1994 
(unreasonable and discriminatory interference of legitimate trade using routes most 
convenient for international transit); and Articles 2, 28, 31, 41 and 42 of the TRIPS 
Agreement, especially in reference to the Doha Declaration and the August 6 Decision 
(unreasonable interference with freedom of transit of generic medicines resulting in 
unnecessary burdens and unwarranted delays and frustrating export of medicines lawfully 
produced to countries where they could be lawfully consumed).   
19
 Marrakesh Agreement Establishing the World Trade Organization, art. 8(1), annex 
1C, Apr. 15, 1994, 1867 U.N.T.S. 154, available at 
http://www.wto.org/english/docs_e/legal_e/27-trips.pdf. 
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Agreement on Tariffs and Trade, the Doha Declaration on the TRIPS 
Agreement and Public Health,
20
 and the Decision of 30 August 30 on 
Paragraph 6 of the Doha Declaration.
21
  At a more fundamental level, legal 
scholars criticized BMR 1383/2003 and the EU‟s multiple seizures of 
generic medicines for violating core features of the international order 
including:  (a) the territoriality of IP rights,
22
 (b) respect for the sovereign 
“independence” of countries to adopt and implement TRIPS-compliant 
patent regimes as they consider appropriate,
23
 (c) freedom of transit of 
goods moving through a country‟s transportation systems in the stream of 
international trade,
24




These issues were placed squarely before the European Court of Justice 
in two joined cases, C-446/09 and C-495/09 Philips/Nokia
26
 adjudicating 
the legality of border actions by customs agents detaining IP-suspect goods, 
temporarily warehoused or placed in external transit procedures, based on 
mere suspicion of diversion and/or reliance on the manufacturing fiction. 
On December 1, 2011, the European Court of Justice issued an opinion
27
 
ruling that goods in customs suspensive procedures, including warehousing 
and external transit, that are suspected of violating trademark, copyright, 
                                                 
20
 Declaration on the TRIPS Agreement and Public Health, Ministerial Conference, 
Fourth Session, Doha, Nov. 9-14 2001, WT/MIN(01)/DEC/1 (Nov 142001), available at 
http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_e.htm. 
21
 Decision of the General Council of Aug. 30, 2003, Implementation of Paragraph 6 
of the Doha Declaration on the TRIPS Agreement and Public Health, WT/L/540 (Sept. 1, 
2003), available at http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm.  
22
 Seuba, supra note 16, at 16-17; Ruse-Khan & Jaeger, supra note 16, at 518-519; 
Abbott, supra note 12, at 44-45.  The territoriality criticism is based on the premise that IP-
related acts done outside a nation‟s territory do not violate the territorial rights in force 
within national borders and that medicines temporarily in-transit do not involve any 
prohibited “use” of the patent (making, using, offering for sale, selling, or importing for 
these purposes) within a country‟s territorial market. 
23
 Seuba, supra note 16, at 16-17; Ruse-Khan & Jaeger, supra note 16, at 521-524; 
Abbott, supra note 12, at 44. 
24
 Seuba, supra note 16, at 9-10; Ruse-Khan & Jaeger, supra note 16, at 532-536; 
Abbott, supra note 12, at 45-46. 
25
 Seuba, supra note 16, at 22-23; Ruse-Khan & Jaeger, supra note 16, at 529-532. 
26
 Case C-446/09, Koninklijke Philips Electronic (2010) OJ C 24/29, (relating to the 
old, superseded Customs Regulation No. 3295/94); and Case C-446/09, Nokia Corporation 
(2010) OJ C 37/22 (relating to BMR 1383/2003). 
27
 Joined Cases C‑446/09 & C‑495/09, Koninklijke Philips Electronics NV v. 
Lucheng Meijing Indus. Co., Nokia Corp. v. Her Majesty‟s Comm‟rs of Revenue and 
Customs, 2011 E.C.R. *** [hereinafter Philips/Nokia Judgment], available at 
http://curia.europa.eu/juris/document/document.jsf?text=&docid=115783&pageIndex=0&d
oclang=en&mode=req&dir=&occ=first&part=1&cid=2701.   
8 India/EU WTO dispute re Seizures of in-transit medicines  
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and design rights under EU Member State law:  (1) could not even be 
temporarily detained in the absence of evidence that the goods had been 
sold, offered for sale or advertised in the EU or that there were other 
indications that operators are about to direct the goods towards European 
Union consumers or were otherwise disguising their commercial intentions; 
and (2) could not be considered abandoned or destroyed unless a 
substantive examination has proven that the challenged goods have been 
sold, offered for sale or advertised to EU consumers or that there is 
documentation showing that diversion is envisaged.
28
  Temporary detention 
requires a showing, “based on the facts of the case”
29
 of a planned or 
advertised sale or a lack of clarity about the intended destination of the 
goods, the identity of the manufacturer or consignee, or a failure to 
                                                 
28
 Id. at ¶79 contains the ruling of the Court: 
Council Regulation (EC) No 3295/94 of 22 December 1994 laying down measures 
concerning the entry into the Community and the export and re-export from the 
Community of goods infringing certain intellectual property rights, as amended by 
Council Regulation (EC) No 241/1999 of 25 January 1999, and Council Regulation 
(EC) No 1383/2003 of 22 July 2003 concerning customs action against goods 
suspected of infringing certain intellectual property rights and the measures to be taken 
against goods found to have infringed such rights must be interpreted as meaning that: 
–        goods coming from a non-member State which are imitations of goods protected 
in the European Union by a trade mark right or copies of goods protected in the 
European Union by copyright, a related right or a design cannot be classified as 
„counterfeit goods‟ or „pirated goods‟ within the meaning of those regulations merely 
on the basis of the fact that they are brought into the customs territory of the European 
Union under a suspensive procedure; 
–        those goods may, on the other hand, infringe the right in question and therefore 
be classified as „counterfeit goods‟ or „pirated goods‟ where it is proven that they are 
intended to be put on sale in the European Union, such proof being provided, inter alia, 
where it turns that the goods have been sold to a customer in the European Union or 
offered for sale or advertised to consumers in the European Union, or where it is 
apparent from documents or correspondence concerning the goods that their diversion 
to European Union consumers is envisaged; 
–        in order that the authority competent to take a substantive decision may 
profitably examine whether such proof and the other elements constituting an 
infringement of the intellectual property right relied upon exist, the customs authority 
to which an application for action is made must, as soon as there are indications before 
it giving grounds for suspecting that such an infringement exists, suspend the release 
of or detain those goods; and 
–        those indications may include, inter alia, the fact that the destination of the 
goods is not declared whereas the suspensive procedure requested requires such a 
declaration, the lack of precise or reliable information as to the identity or address of 
the manufacturer or consignor of the goods, a lack of cooperation with the customs 
authorities or the discovery of documents or correspondence concerning the goods in 
question suggesting that there is liable to be a diversion of those goods to European 
Union consumers. 
29
 Id.  at ¶ 62. 





 Final proof of a substantive EU IP violation 
will in turn depend on firm, documented evidence of actual or planned 
diversion.
31
  This judgment by the Court should constitute a death knell for 
the “manufacturing” or “production” fiction that was used to justify seizure 




III. CRITIQUE OF THE PROPOSED BORDER REGULATION – BETTER IS NOT 
GOOD ENOUGH 
 
This is not the time to rehash the comprehensive critique of BMR 
1383/2003, but rather to assess whether the Proposed Border Regulation 
ameliorates its harsh and unwarranted application of customs detention to 
in-transit generic medicines.  Although the Proposed Border Regulation 
improves due process  to deter patent holders‟ abuse of border measures,
33
 
recognizes the Doha Declaration,
34
 and requires prompt court action 
                                                 
30
 Id. at ¶¶ 59, 60. 
31
 Id. at ¶¶ 68, 71. 
32
 See at ¶ 69. 
33
 See Proposed Border Regulation, supra note 6.  New due process protections 
include: right holder liability to declarants or the holder of the goods for wrongful 
applications where the goods are determined not to be IP-infringing, but only if domestic 
law so provides (Art. 26); reimbursement to the state for costs of destruction (Art. 27); time 
limits on detentions pending decision on an application (Arts. 10 & 11); and goods holder 
(alleged infringer) right to be heard (Arts. 16, 17 & 24).  See generally Recital No. 15:   
For further legal clarity and in order to protect the interests of legitimate 
traders from possible abuse of the border enforcement provisions, it is appropriate 
to modify the timelines for detaining goods suspected of infringing an intellectual 
property right, the conditions in which information about consignments is to be 
passed on to right-holders by customs authorities, the conditions for applying the 
procedure allowing for destruction of the goods under customs control for 
suspected infringements of intellectual property rights other than for counterfeit 
and pirated goods and to introduce a provision allowing the holder of the goods to 
express his/her views before the customs administration takes a decision which 
would adversely affect him/her. 
Collectively these procedural protections, though improvements, do not totally 
ameliorate the risk of abusive applications for detention of goods nor remedy the harm 
not only to declarants and holders of the goods but also to purchasers of essential life-
saving medicines and their ultimate consumers who may suffer adverse health effects 
because of the interception of legitimate in-transit medicines.   
34
 Proposed Border Regulation, supra note 6 at Recital No. 17:  
Under the "Declaration on the TRIPS Agreement and Public Health" adopted 
by the Doha WTO Ministerial Conference on 14 November 2001, the TRIPS 
Agreement can and should be interpreted and implemented in a manner supportive 
of WTO Members' right to protect public health and, in particular, to promote 
10 India/EU WTO dispute re Seizures of in-transit medicines  
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regarding detentions based on suspected patent violations,
35
 the proposal 
still contains disruptive measures. These measures unjustifiably interfere 
with the legitimate trade of generic medicines of assured quality, and cause 
harm to vendors and shippers of the goods and to their purchasers and 
consumers.  It contains these negative features despite the efforts of leading 
NGOs and commentators urging more extensive reforms that would have 
eliminated the risks of patent-based and civil-trademark-based seizures of 
generic medicines in transit.
36
 
Problems with the Proposed Border Regulation include: 
 
1. The proposed regulation continues coverage of patents, 
supplementary protection certificates for medicinal products 
(patent extensions), design rights, and civil trademark 
infringements, and thus continues to threaten access to 
medicines.
37
   
In fact, the proposal extends border measures to entirely new 
intellectual property rights, including trade names, topographies of 
semiconductor products, utility models, and devices to circumvent 
technological measures, as well as any exclusive intellectual 
                                                                                                                            
access to medicines for all. …” 
It is important to note that this recital is preambular and imposes no direct 
obligation on an EU Member State.  
35
 Id. at Recital 11; Art. 20.   
Where goods suspected of infringing intellectual property rights are no 
counterfeit or pirated goods, it may be difficult to determine upon mere visual 
examination by customs authorities whether an intellectual property right might be 
infringed.  It is therefore appropriate to provide that proceedings should be 
initiated, unless the parties concerned, namely the holder of the goods and the 
right-holder, agree to abandon the goods for destruction.  It should be for the 
competent authorities dealing with such proceedings to determine whether an 
intellectual property right has been infringed and to take appropriate decisions 
concerning the infringements of intellectual property rights concerned. 
36
 See, e.g., Thomas Jaeger, Henning Grosse Ruse-Khan, Josef Drexl & Reto M. Hilty, 
Statement of the Max Planck institute for Intellectual Property, Competition and Tax Law 
on the Review of EU Legislation on Customs Enforcement of Intellectual Property Rights 
(2010), available at http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1622619; Letter 
from Public Citizen to European Commission (May 25, 2010), available at 
http://www.citizen.org/documents/Public%20Citizen%20comments%20submitted%20to%
20DG%20TAXUD%20on%201383.pdf; Oxfam International, Public Consultation on the 
Review of Council Regulation 1383/2003 (2010), available at 
http://circa.europa.eu/Public/irc/taxud/consultation_ipr/library?l=/registered_organisations/
stichting_international/_EN_1.0_&a=d.  Most civil society comments focused primarily on 
the desirability of excluding patent rights from any revision of BMR 1383/2003.  
37
 Proposed Border Measure, supra note 6, Art. 2(1)(e) & (f). 
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property rights established by Union legislation in the future.
38
  
Instead of continuing to cover patents, supplementary protection 
certificates and expanding coverage to include utility models, civil 
trademark rights, and design rights, the scope of the Proposed 
Border Regulation should be restricted to criminal trademark 
counterfeiting and copyright piracy as defined by Articles 61 and 51 
footnotes 14(a) and (b) of the TRIPS Agreement.
39
  Coverage of 
patents, supplementary protection certificates, utility models, design 
rights, and civil trademark rights should be explicitly excluded.  By 
adopting such a limited, scope, the Proposed Border Regulation 
would prevent seizures of generic medicines because of weak, 
invalid or non-existent patent or utility model claims or because 
confusing similarity in trade name, trademark, or trade dress.
40
  
Moreover, it would leave ordinary commercial disputes involving 
complex facts and IP rules to judicial resolution in the country of 
                                                 
38
 Id. Recital 5; Art. 2(1)(j)-(m). 
39
 TRIPS, supra note 2019, Article 51 n. 14 reads:   
For the purposes of this Agreement: 
(a) “counterfeit trademark goods” shall mean any goods, including packaging, 
bearing without authorization a trademark which is identical to the 
trademark validly registered in respect of such goods, or which cannot be 
distinguished in its essential aspects from such a trademark, and which 
thereby infringes the rights of the owner of the trademark in question 
under the law of the country of importation (emphasis added); 
(b) “pirated copyright goods” shall mean any goods which are copies made 
without the consent of the right holder or person duly authorized by the 
right holder in the country of production and which are made directly or 
indirectly from an article where the making of that copy would have 
constituted an infringement of a copyright or a related right under the law 
of the country of importation. 
TRIPS Article 61, in relevant part reads:  
Members shall provide for criminal procedures and penalties to be applied at 
least in cases of willful trademark counterfeiting or copyright piracy on a 
commercial scale. Remedies available shall include imprisonment and/or 
monetary fines sufficient to provide a deterrent, consistently with the level of 
penalties applied for crimes of a corresponding gravity. In appropriate cases, 
remedies available shall also include the seizure, forfeiture and destruction of the 
infringing goods and of any materials and implements the predominant use of 
which has been in the commission of the offence. (Emphasis added.) 
40
 Some health officials are now arguing that it may be desirable to encourage generic 
equivalents to have the same appearance or trade (size, shape, and color of the medicine) so 
as to promote generic substitution and reduce prescription errors by pharmacists, to avoid 
patient confusion, and to enhance patient adherence.  Jeremy A. Greene & Aaron S. 
Kesselheim, Why Do the Same Drugs Look Different?  Pills, Trade Dress, and Public 
Health, 365 NEW ENGL. J. MED. 83-89 (2011).   
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importation pursuant to the governing laws of that country as 
required by TRIPS.   
 
2. The Proposed Border Regulation continues to authorize 
application of the law of the transit country and the use of the 
manufacturing fiction, both of which inappropriately permit the 
seizure of generic medicines in transit.  
Under the Proposed Border Regulation, the definition of "goods 
suspected of infringing an intellectual property right” means “goods 
with regard to which there is adequate evidence to satisfy customs 
authorities that, in the Member State the goods are prima facie:  
goods which are subject to an action infringing an intellectual 
property right under the law of the Union or of that Member State 
(emphasis added).”
41
  More precisely, the applicable law used to 
determine whether “the use of … goods gives rise to suspicion of 
infringement of an intellectual property right or has infringed an 
intellectual property right” is that of “the law [of the] Member State 
where the goods are found” (emphases added).
42
 This formulation is 
slightly different than the formulation of  Recital No. 8 of BMR 
1383/2003 which stated that “[p]roceedings initiated to determine 
whether an intellectual property right has been infringed under 
national law will be conducted with reference to the criteria used to 
establish whether goods produced in that Member State infringe 
intellectual property rights (emphasis added).”  The use of the 
phrase “use of those goods” versus “goods produced” would not 
seem to directly undermine the continuing viability of the 
manufacturing fiction under national law.  For example, Article 28 
of the TRIPS Agreement covers both “manufacturing” (production) 
and “use.”
43
  Moreover, the Proposed Border Regulation is clear that 
                                                 
41
 Proposed Border Measure, supra note 6, Art. 2(7)(a).  Although this language is 
somewhat confusing, its main import is that the law of individual EU Member States will 
continue to apply.   
42
 Id. Art. 3  
Applicable Law:  … the law of the Member State where the goods are found 
in one of the situations referred to in Article 1(1) shall apply for the purpose of 
determining whether the use of those goods gives rise to suspicion of infringement 
of an intellectual property right or has infringed an intellectual property right 
(emphasis added).  
  
43
 TRIPS, supra note 2119: 
A patent shall confer on its owner the following exclusive rights:  (a) where the 
subject matter of a patent is a product, to prevent third parties not having the owner‟s 
consent from the acts of: making, using, offering for sale, selling, or importing for 
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it is not intended to affect in any way the laws of Member States.
44
 
Accordingly, if a country maintains the manufacturing fiction with 
respect to assessing the patent or supplementary protection status of 
a medicine, as the Netherlands and other European countries clearly 
do,
45
 then an in-transit generic medicine could still be seized, 
adjudicated as an infringement, and thus destroyed, even if it was 
lawfully produced in the country of manufacture and destined for 
legal use in the final country of import.  This fictive, non-territorial 
application of domestic law to transit goods is in direct violation of 
Articles 52
46
 and 51, footnote 14
47
 of the TRIPS Agreement, which 
requires application of “the law of the importing country” when 
assessing whether an intellectual property right at the border is 
violated or whether a good is a trademark counterfeit. There is no 
justification for applying fictive domestic IP law to goods that are 
not “used” so as to violate IP rights within the territorial market of 
the transit country.  Applying such fictive rights, in essence becomes 
an extra-territorial application of purely domestic IP law and IP 
status to goods that are destined for commercialization or other use 
within that territory.  To apply such fictive territorial rules could 
disrupt broad swathes of international trade using the most efficient 
trade routes as permitted by GATT.  Dangerously, there is no reason 
that such fictive territoriality could not be extended with respect to 
other territorial regimes including labor rights, environmental rights, 
packaging/disclosure requirements, licensure, etc. Finally, any 
continued use of the manufacturing fiction should now be decisively 
illegal pursuant to the recent judgment of the European Court of 
Justice.
48
   
 
 
                                                                                                                            
these purposes that product; (b) where the subject matter of a patent is a process, to 
prevent third parties not having the owner‟s consent from the act of using the 
process, and from the acts of: using, offering for sale, selling, or importing for these 
purposes at least the product obtained directly by that process. 
44
 Proposed Border Measure, supra note 6, Art. 1.3. 
45
 Olivier Vrins, The Real Story of a Fiction:  Transit after Montex under Regulation 
(EC) 1383/2003, 5 J. INTELLECTUAL L. & PRAC. 358, 358-371 (2010). 
46
 TRIPS, supra note 19, Art. 52:  “Any right holder initiating the procedures under 
Article 51 shall be required to provide adequate evidence to satisfy the competent 
authorities that, under the laws of the country of importation, there is prima facie an 
infringement of the right holder‟s intellectual property right ….” 
47
 See supra note 37. 
48
 See supra notes 27-33. 
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3. The exhortation for customs authorities to acknowledge 
transshipment as occurring within the context of international 
trade, and to "take account of any substantial likelihood of 
diversion [of medicines] onto the market of the Union,"
49
 has no 
teeth and has no meaningful definition of how the likelihood of 
diversion is to be established.  
Although Recital 17 says that customs authorities “should” take into 
account any substantial likelihood of diversion, it does not require 
them to do so. Likewise, although the actuality of imminent 
diversion into the European market is the only legally permissible 
basis upon which to base the territorial application of European IP 
status for a particular product, there is no guidance on what level or 
type of evidence of diversion would suffice. Mere suspicion of 
diversion should clearly be insufficient, but should there instead be 
evidence of planned purchase and distribution by an identified entity 
within the domestic market? Would it be sufficient to show a past 
practice of diversion by the manufacturer or distributor of the same 
good in the recent past?  All of these questions need to be directly 
addressed and clarified at the very least by adopting explicitly the 
framework adopted by the European Court of Justice.
50
  Even the 
Court of Justice‟s ruling is undesirably weak with respect to 
authorizing temporary detention pending final adjudication of 
planned diversion directed at EU consumers. Accordingly, the 
proposed “evidence of diversion” provision justifying even 
temporary detention would be substantially strengthened if it were 
incorporated into the actual text of the regulation itself and if it were 
to say:  “There may be no determination of prima facie suspicion of 
or violation of a covered intellectual property right in the absence of 
compelling evidence showing a substantial likelihood of imminent 
diversion of the challenged goods by an identified party onto the 
market of the European Union.” 
 
                                                 
49
 Proposed Border Measure, supra note 6, Recital 17.   
In particular with regard to medicines the passage of which across this 
territory of the European Union, with or without transshipment, warehousing, 
breaking bulk, or changes in the mode or means of transport, is only a portion of a 
complete journey beginning and terminating beyond the territory of the Union, 
customs authorities should, when assessing a risk of infringement of intellectual 
property rights, take account of any substantial likelihood of diversion of these 
goods onto the market of the Union. 
50
 See supra notes 27-33. 
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4. The time period for declarants or the holder of goods to respond 
to detention of suspect goods is too short.   
Temporary suspension of the release of goods or their detention can 
be pursued ex parte either by an application of the right-holder or 
other identified surrogate using Articles 4-6 or by unilateral ex 
officio action of customs authorities, who thereafter must request the 
right holder to initiate an application, Article 17.  In either event, 
customs authorities are required to communicate their intentions to 
the declarant or, in the case of detention, the holder of the goods 
after the fact, and only then is the declarant or holder “given the 
opportunity to express his/her views within three working days.”
51
  
Upon granting an application, the competent customs department 
must suspend the release of the goods or detain them and must 
promptly notify both the holder of the decision (the right holder) and 
the declarant or holder of the goods of its decision.
52
    Although 
these notice and opportunity to be heard provisions are an 
improvement over BMR 1383/2003, the three-day time period 
granted to declarants and holders of the goods is insufficient to give 
them fair opportunity to amass evidence concerning the lawful IP 
status of the goods in issue and to confirm the ultimate destination 
of in-transit goods outside the EU.  Declarants and holders of goods 
should be given at least 10 days for such a showing and there should 
be additional provisions allowing for a further extension upon 
proper motivation. 
 
5. Even temporary detention of generic medicines adversely affects 
the rights of intended purchasers and users and the Proposed 
Border Regulation leaves them without a remedy.   
A further requirement applying to non-counterfeit or pirated goods 
(criminal trademark and copyright violations) – namely goods 
alleged to have infringed design, patent, supplementary protection 
certificates, utility model, or plant variety rights – is that they must 
initiate proceedings for a court decision determining that the IP right 
in question has been violated.
53
 However, the requirement of 
additional court proceedings does not prevent pre-determination 
seizure either upon application of the right-holder or even ex officio 
                                                 
51
 Id. at Arts. 16.3 & 17.3.  A longer time period of 20 days is granted when customs 
officials propose to destroy goods in small consignments.  Art. 24.4.   
52
 Id. at Arts. 16.4, 17.4. 
53
 Id. at Art. 20.1. 
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by the customs authority.  Admittedly, the goods will be detained, 
pursuant to a granted application, for only a limited period of time – 
10 days – unless proceedings are promptly initiated, but goods 
thereafter can ordinarily be detained until the court proceedings have 
ended, a time period that can last months or even years.
54
  There are 
procedures for release of goods upon payment of adequate security, 
and there are eventual remedies for applications and proceedings 
where it is determined that IP rights have not been violated, but 
these partial remedies do not always compensate holders of the 
goods for lost commercial opportunities and disruptions of their 
business, nor do they provide remedies for intended purchasers and 
ultimate consumers whose needs for life-saving and health-
enhancing medicines have been frustrated. Buyers, including 
government purchasers might have to use special and higher cost 
procurement methods to get emergency supplies. If they are fiscally 
unable to do so, or if suppliers cannot meet their needs immediately 
because of orders from other customers, public health programs and 
the immediate medical needs of patients might not be met. At 
present, there are no remedies for such purchasers or consumers, nor 
even are there confirmed remedies for declarants or holders of goods 
unless, and only to the extent that, the law of the country in question 
so provides.
55
 The Proposed Border Regulation should be amended 
to provide much more certain and robust remedies for declarants and 
holders of goods and for purchasers and customers who may have 
suffered harm as a proximate result of right-holders‟ unsuccessful 
actions under the regulation. 
 
 
                                                 
54
 This ten-day period can be extended another ten days upon application except in the 
case of perishable goods.  Id. at Art. 20.4. There are provisions for the declarant or holder 
of the goods to seek their release from detention, but only if adequate security has been 
posted, no precautionary measures (preliminary injunctions) have been entered, and all 
customs formalities completed;  Art. 21.1. 
55
 Id. at Art. 26: 
Where a procedure duly initiated pursuant to this Regulation is 
discontinued owing to an act or omission on the part of the holder of the 
decision granting the application or where the goods in question are 
subsequently found not to infringe an intellectual property right, the holder of 
the decision granting the application shall be liable towards the persons 
involved in a situation referred to in Article 1(1) in accordance with the 
legislation of the Member State where the goods were found. 





A better regulation would have excluded coverage of patents, 
supplementary protection certificates, utility models, design rights, and civil 
trademark violations and/or specifically prevented application of a domestic 
manufacturing or use fiction with respect to in-transit goods.  It would have 
much more directly addressed the Doha Declaration and clarified that no 
customs action should be undertaken with respect to in-transit generic 
medicines lawfully produced in the country of origin and lawfully imported 
into the country of use, unless there is concrete and compelling evidence of 
imminent diversion of the goods into the European market by an identified 
party.  Declarants and holders of goods should be given more meaningful 
opportunities to object to detention and seizure of their goods and to oppose 
applications by right holders. And, the provisions for remedies when right 
holders‟ applications are unsuccessful should be expanded both for 
declarants/holders-of-goods and ultimate purchasers/consumers whose 
interests have been proximately harmed by the wrongful detention and/or 
destruction of goods.   
Instead, the EC has attempted to strengthen the enforcement rights of IP 
right holders and has once again passed the buck to country-specific IP 
legislative standards and enforcement criteria. These country specific 
standards and criteria, including the manufacturing/domestic-use fiction, 
may once again run afoul of fundamental precepts of intellectual property 
law, the TRIPS Agreement and GATT, and public health needs enshrined in 
the Doha Declaration and in other binding human rights instruments.  
Europe has treated its reform obligations primarily as an exercise in 
balancing expanded intellectual property protections against greater due 
process rights, without addressing the most fundamental defects in the BMR 
1383/2003 regime, a defect that has also been identified by the European 
Court of Justice.  Accordingly, European parliamentarians should reject the 
Proposed Border Regulation in its current form as should India and Brazil 
with respect to their suspended WTO complaints. 
 
 
 
